Aromatase Inhibitor–Related Symptoms Reported by Postmenopausal Women with Nonmetastatic, Estrogen Receptor–Positive Breast Cancer: A Systematic Review

Ayanian, 2006, Enhancing research on cancer survivors, J Clin Oncol, 24, 5149, 10.1200/JCO.2006.06.7207 2001, Tamoxifen for early breast cancer, Cochrane Database Syst Rev Definition of PRO - NCI Dictionary of Cancer Terms - NCI, (n.d.). Accessed July 11, 2023. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pro Burstein, 2018, Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update, J Clin Oncol, 37, 423, 10.1200/JCO.18.01160 Cardoso, 2019, Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 1194, 10.1093/annonc/mdz173 Laugsand, 2010, Health care providers underestimate symptom intensities of cancer patients: a multicenter European study, Health Qual Life Outcomes, 8, 10.1186/1477-7525-8-104 Guner, 2014, Comparison of the symptoms reported by post-operative patients with cancer and nurses’ perception of patient symptoms, Eur J Cancer Care (Engl), 23, 523, 10.1111/ecc.12144 Miyajima, 2014, Symptoms overlooked in hospitalized cancer patients: Impact of concurrent symptoms on oversight [corrected] by nurses, Palliat Support Care, 12, 95, 10.1017/S1478951512001009 Valikodath, 2017, Agreement of ocular symptom reporting between patient-reported outcomes and medical records, JAMA Ophthalmol, 135, 225, 10.1001/jamaophthalmol.2016.5551 Salas, 2022, Health-related quality of life in women with breast cancer: a review of measures, BMC Cancer, 22, 10.1186/s12885-021-09157-w Basch, 2014, Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE), J Natl Cancer Inst, 106, 10.1093/jnci/dju244 Zhu, 2019, Symptom map of endocrine therapy for breast cancer: a scoping review, Cancer Nurs, 42, E19, 10.1097/NCC.0000000000000632 Page, 2021, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ, 372 NCI Dictionary of Cancer Term. Accessed November 6, 2022. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/symptom. Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 3, 365, 10.1093/jnci/85.5.365 Hong QN, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal Tool (MMAT) version 2018 user guide. Laroche, 2014, Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study, J Pain, 15, 293, 10.1016/j.jpain.2013.11.004 Shi, 2013, Anastrozole-associated joint pain and other symptoms in patients with breast cancer, J Pain, 14, 290, 10.1016/j.jpain.2012.11.010 Lubián López, 2021, Sexual dysfunction in postmenopausal women with breast cancer on adjuvant aromatase inhibitor therapy, Breast Care, 16, 376, 10.1159/000510079 Oberguggenberger, 2011, Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs), Breast Cancer Res Treat, 128, 553, 10.1007/s10549-011-1378-5 Tane, 2017, Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes, Breast Cancer, 24, 528, 10.1007/s12282-016-0735-y Gibson, 2020, Dry eye signs and symptoms in aromatase inhibitor treatment and the relationship with pain, Ocul Surf, 18, 108, 10.1016/j.jtos.2019.10.008 Nugent, 2016, The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy, Support Care Cancer, 24, 3401, 10.1007/s00520-016-3161-y Egawa, 2016, Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes, Int J Clin Oncol, 21, 262, 10.1007/s10147-015-0905-5 Olufade, 2015, Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors, Support Care Cancer, 23, 447, 10.1007/s00520-014-2364-3 Gehrman, 2017, Insomnia in breast cancer: independent symptom or symptom cluster?, Palliat Support Care, 15, 369, 10.1017/S1478951516000900 Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Resolution Concerning Updating the International Standard Classification of Occupations, (n.d.). Fallowfield, 2007, Quality of life issues in relation to the aromatase inhibitor, J Steroid Biochem Mol Biol, 106, 168, 10.1016/j.jsbmb.2007.05.003 EORTC – Quality of Life. Accessed December 14, 2022. https://qol.eortc.org/item-library/ PROMIS: Clinical Outcomes Assessment. Accessed December 14, 2022. https://commonfund.nih.gov/promis/index.